HTA Quarterly | Fall 2022
By HTA Quarterly
In this issue, our editors provide insights on the new European Union health technology assessment (HTA) regulation, an analysis of the use of health economics to respond to the COVID-19 pandemic, and a review of Germany’s newly adopted Statutory Health Insurance Financial Stabilization Act.
.jpg?h=3299&iar=0&w=5000&hash=03BAD8086A4A080FF9D341B726210C94)
HTA Quarterly | Fall 2022
The new EU regulation on health technology assessment: Major change or minor adjustment?
HTA Quarterly | Fall 2022
Did health economics fail us during the COVID-19 pandemic?
Are the measures taken to manage COVID-19 cost-effective? Should this question even be raised when lives are at stake? In reality, budgets are finite and cost-benefit decisions are taken by healthcare policy makers every day to prioritize resources. So, did health economics step up to the plate during the COVID-19 pandemic?
HTA Quarterly | Fall 2022
Upcoming cost-containing measures in Germany—How will they affect the biopharmaceutical industry?
Xcenda original research on alopecia areata
It’s bigger than the US: A global perspective on alopecia areata
Alopecia areata (AA), an autoimmune disease that may result in hair loss, affects any gender and all skin types. Approximately 0.1%–0.58% of the world’s population is diagnosed with AA. AA is unpredictable and found to be more prevalent in younger age groups. The more extensive the hair loss becomes, the more likely the disease will become chronic and not remit without treatment. Thinking of AA as simply hair loss fails to acknowledge the suffering experienced by many patients.
Prior to the recent approval of the first Janus kinase (JAK) inhibitor for AA, there were no regulatory-approved treatments available for patients with AA. This results in high out-of-pocket cost for patients on top of their already high financial, psychological, and social burden.
Xcenda took a global perspective on AA and examined the steps needed to manage the major life impact AA has on patients. As medical science progresses in developing a treatment for AA, payers and policymakers should recognize that AA may have severe and lifelong psychological, emotional, and other impacts on patients. The paper addresses actions to ensure appropriate and equitable access to treatments once they become available.
Heard on the street
